Sera Prognostics (SERA) to Release Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is expected to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect Sera Prognostics to post earnings of ($0.23) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Sera Prognostics Stock Performance

Sera Prognostics stock opened at $4.14 on Tuesday. The company’s 50 day simple moving average is $5.22 and its 200-day simple moving average is $6.64. The company has a market capitalization of $139.82 million, a price-to-earnings ratio of -4.18 and a beta of 0.89. Sera Prognostics has a 1 year low of $3.84 and a 1 year high of $12.36.

Insider Activity

In related news, insider Robert Gardner Harrison sold 14,209 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $7.39, for a total transaction of $105,004.51. Following the sale, the insider now directly owns 116,837 shares of the company’s stock, valued at $863,425.43. This represents a 10.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joshua Phillips sold 12,163 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the sale, the director now directly owns 2 shares in the company, valued at approximately $12.78. The trade was a 99.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,877 shares of company stock valued at $480,677. Company insiders own 15.80% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.